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Abstract
Background: High resolution ultrasonography (HR-US) can monitor the molecular changes and
biochemical interactions between proteins in real-time. The aim of this study was to use HR-US to
characterize the real-time interactions between plasminogen coated beads and PrPSc and to
determine if this approach could be applied to the identification of animals affected by prion
diseases. Plasminogen, immobilized to beads, was used as a capturing tool for PrPSc in brain
homogenates from scrapie affected sheep and the binding reaction was monitored in real-time in
an ultrasonic cell.
Results: Changes in the ultrasonic parameters suggested that three processes occurred during the
incubation: binding, protein-protein network formation and precipitation and that these processes
occurred in a concentration dependent manner. Conversely, when homogenates from normal
sheep were similarly examined, no evidence for the occurrence of these processes was found
indicating the specificity of the interaction between the plasminogen coated beads and PrPSc.
Conclusion: These results indicate firstly, that the plasminogen coated beads binded selectively to
PrPSc and secondly, that a HR-US system can discriminate between scrapie affected and non-
affected samples and thus has potential as a tool for the rapid diagnosis for prion diseases. This
approach has the significant advantage of not requiring a proteinase K pre-digestion step, which is
routinely used in current PrPSc detection assays.
Background
Prion diseases such as CJD in humans, BSE in cattle and
scrapie in sheep are a group of neurodegenerative disor-
ders, which are characterised by the accumulation in the
central nervous system of the protease resistant form
(PrPSc) of a host-coded membrane glycoprotein (PrPc) [1].
The transformation of PrPc into PrPSc implies a conforma-
tional change from a mainly alpha helical form into a beta
sheet rich structure [2,3]. This conformational difference
is responsible for the distinct physicochemical properties
of both isoforms. While PrPc exist as a monomer and it is
rapidly degraded by proteinase K (PK), the infectious iso-
form PrPSc, forms detergent-insoluble aggregates and dis-
plays a higher resistance to degradation with PK [4,5].
Most currently used diagnostic techniques are based on
the immunological detection of PrPSc using antibodies
specific to the prion protein. As antibodies used on cur-
rent validated assays are not able to differentiate between
PrPSc and PrPc, these diagnostic procedures rely on the
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elimination of PrPc by PK digestion, PrPSc remaining due
to its PK resistance. However, the use of PK sample pre-
treatments may compromise the sensitivity of an assay as
some PrPSc conformations are known to be relatively pro-
tease-sensitive.
Many recent investigations are focused on increasing the
sensitivity of current diagnosis assays and much effort has
been directed toward the development of novel reagents
that could be used as sensitive tools for prion detection.
Several such reagents, aimed at the specific detection of
PrPSc, include nucleic acid-aptamers [6], anti-DNA anti-
bodies [7], PrPSc specific monoclonal antibodies antibod-
ies [8,9] and plasminogen protein [10].
Plasminogen, a plasma proenzyme involved in the proc-
ess of fibrinolysis [11], has shown potential for the detec-
tion and differentiation of PrPSc without the necessity for
a PK pre-treatment. The specific binding of plasminogen,
covalently bound to magnetic beads, to PrPSc aggregates in
tissues from several species has been demonstrated
[10,12]. While binding of PrPc may occur, PrPSc is prefer-
entially bound under experimental conditions that
enhance the formation of fibrils [13].
High-resolution ultrasonic spectroscopy is a novel real-
time analytical non-destructive technique for material
analysis, in which changes in the behaviour of ultrasonic
waves, as they pass through a test material, may provide
information regarding the structure and composition of
the material. Ultrasonic spectroscopy allows simultane-
ous measurements of two independent parameters: veloc-
ity and attenuation, both of which are very sensitive to
changes in intermolecular interactions and molecular
organization. Attenuation is a measure of the energy loss
in the compressions and decompressions produced as an
ultrasonic wave passes through a material and gives infor-
mation on the microscopic structural organisation of the
material. Ultrasonic velocity is a measurement of the den-
sity and elastic response of the material to the oscillating
pressure and provides information regarding its molecu-
lar organization. The ability of an ultrasonic system to
monitor both structural and chemical processes in real
time has been demonstrated. For example, it has been
shown to be well suited to a wide range of applications
such as the study of aggregation and gelation in food col-
loids, conformational transitions in polymers and biopol-
ymers, and phase transitions and formation of micelles
[14-18]. It has also been recently applied to the analyses
of chemical reactions [19,20]. Advantages of this tech-
nique include the ability of the ultrasonic wave to propa-
gate through a broad range of samples, including opaque
materials (in contrast to optical spectroscopy), and the
opportunity to carry out on line analysis because ultra-
sonic detection can be done without pre-treatment of the
material. Another distinct advantage is the high resolution
in measurements of velocity, allowing detection of con-
centrations down to ppm level.
A combination of specific reagents for the disease associ-
ated prion protein and this novel ultrasonic technique
make this approach extremely promising for the analysis
and diagnosis of prion disease. Thus, the aim of this study
was to investigate the interactions between plasminogen
coated beads and PrPSc in scrapie affected brain tissue, par-
ticularly in the absence of a proteinase K pre-digestion
step, with a view to exploring its potential for use as a sen-
sitive detection system for PrPSc.
Results
The interaction of PrPSc to plasminogen was analyzed in
real time using the ultrasonic spectroscopy measurements
of velocity and attenuation. In each experiment, the evo-
lution of ultrasonic profiles was investigated over a period
of approximately four hours after the addition of a plas-
minogen coated bead solution (10 μl added giving a final
concentration of 2 × 107) or alternatively in the absence of
beads. Specificity was demonstrated using uncoated
beads. In a first series of experiments, binding kinetics
were analyzed by titration of PK undigested homogenates
at three concentrations 10, 5 and 2%. As the 2% homoge-
nate gave the clearest results, all further experimentation
focused on this concentration and only these results are
reported here. Similarly, velocity measurements gave the
most valuable information; attenuation measurements
failed clearly to differentiate different homogenate varia-
bles. Thus, only the results of the velocity measurements
are presented here.
PK untreated homogenates
In scrapie affected, PK untreated homogenates, velocity
profiles demonstrated three distinct stages during the
incubation period (see Figure 1). The first stage is charac-
terized by an increase in the velocity values, reaching a
peak after about 40 minutes. The second stage was charac-
terized by an extended plateau period, lasting approxi-
mately 90 minutes and finally there was a sharp decrease,
taking about 10 to 20 minutes to reach T0 levels. This pat-
tern of binding was found consistently in repeat experi-
ments.
By contrast, scrapie unaffected homogenates gave profiles
(Figure 1) which were quantitatively and qualitatively dis-
tinct from those of affected samples (P < 0.05). They
showed a gradual but small increase over the four hour
period of study and were very similar to those of the con-
trol samples, both scrapie affected and unaffected, which
were performed in the absence of beads (Figure 1).BMC Biotechnology 2007, 7:43 http://www.biomedcentral.com/1472-6750/7/43
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Thus, it was only in the scrapie affected tissues that there
evidence of a significant reaction and these results argue
for an interaction between the plasminogen coated beads
and PrPSc but not between the plasminogen coated beads
and PrPc or any non-PrP component of the sample.
Effect of PK
Further studies to investigate the specificity of the velocity
profiles were performed using PK-treated homogenates.
By contrast to the three-phase velocity profile seen with
PK untreated scrapie positive tissues, PK appears to have
the effect of eliminating the plateau phase giving instead,
a two-phase reaction. This comprised firstly a gradual
increase over a period of ~70 minutes and followed by a
sudden decrease, taking ~10 minutes to reach T0. The
amplitude of the Phase-1 increase in these PK treated tis-
sues was always less than that seen in the PK untreated.
Velocity profiles in scrapie unaffected tissues showed no
evidence of any reaction and no significant difference was
seen between those which were PK treated and those
untreated (P > 0.05).
Discussion
The ability of plasminogen coated beads to selectively
bind PrPSc was confirmed in experiments involving PK-
treated healthy and PK-treated infected brain samples. The
results of the PK-treated healthy samples, which showed
no evidence of any binding, indicated that no non-PrP
molecule is bound by the plasminogen coated beads.
Thus, in PK treated homogenates, only PrPSc is bound to
plasminogen. In experiments involving PK untreated
homogenates, we have demonstrated that no binding
occurs in healthy samples, indicating that PrPc does not
bind in these reaction conditions. By contrast, in PK
untreated scrapie affected samples, there is good evidence
that PrPSc is bound to plasminogen. These results corrob-
orate previous investigations, which indicated a selective
binding response of plasminogen to PrPSc [10,12] demon-
strating the feasibility of plasminogen and the potential of
this technique to be used as a diagnostic tool to differen-
tiate between PrP isoforms.
Controversial to these results are the studies of Ellis et al.
[21], Ryou et al. [22], Kornblatt et al. [23], and Cuccioloni
et al. [24]. These investigations, performed with recom-
binant prion protein as well as purified full-length PrPc,
suggested that PrPc could also interact with plasminogen.
Illustration of ultrasonic velocity (dU) profiles of PK-untreated scrapie infected and healthy brain homogenates prepared at 2%  in the presence and absence of plasminogen coated beads Figure 1
Illustration of ultrasonic velocity (dU) profiles of PK-untreated scrapie infected and healthy brain homogenates prepared at 2% 
in the presence and absence of plasminogen coated beads. Binding reaction was performed in the reaction buffer at 25°C. A 10 
ul-buffer solution with coated beads (2 × 107) or without (0) was added to each sample (t = 0). Ultrasonic profiles of scrapie 
infected homogenate in the presence (black triangle) and absence (grey triangle) of beads and healthy brain homogenates in the 
presence (black circle) and absence of beads (grey circle) are shown over approximately 3-hour of the reaction.
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The apparently contradictory evidence might be explained
by the different binding properties of plasminogen kringle
domains to PrP in varying detergent conditions. It has
been suggested that the preferential binding of plasmino-
gen to one PrP isoform or another depends of the physical
state of PrP in the particular detergent solution [12,22].
Fischer et al. [10] and Maissen et al. [12] pointed out that
the high amyloid content of PrPSc and/or its aggregated
state could have favored the binding of plasminogen to
the PrPSc isoform over the soluble PrPc form. Thus, the
binding of prion isoforms to plasminogen is affected by
the detergent extraction conditions. Shaked et al. [13]
reported that the selective binding of plasminogen to
PrPSc occurs under detergent conditions that cause raft dis-
ruption and enhance the aggregate state of PrPSc. These
authors reported that PrPc, extracted from natural sources,
was able to interact to plasminogen only in detergent con-
ditions in which rafts remained intact. In the present
study, homogenates were prepared in Sarkosyl, an anionic
detergent which promotes aggregation, and most likely,
solubilises rafts [25,26]. It is therefore likely that the reac-
tion conditions used in this study promoted the interac-
tion of plasminogen and the aggregated PrPSc isoform.
There was no evidence that endogenous palsminogen
would interfere with this assay in this study as all five
scrapie positive tissues interacted with the plasminogen
coated beads.
Although velocity profiles of both PK-untreated and
treated scrapie infected samples revealed binding, com-
plex formation and precipitation, the magnitude of veloc-
ity changes, rate of binding and time intervals at which
precipitation occurs varied between samples. Conclusions
could not be drawn in accordance with the quantitative
kinetics of rate of binding in those curves as the accurate
concentration of protein and therefore the number of
binding sites on the surface is unknown. However, com-
parative qualitatively analyses of velocity profiles of PK-
treated and untreated samples revealed that the rate of
binding and magnitude of change in velocity was higher
and faster in PK-untreated samples than PK-treated sam-
ples. In contrast, the precipitation of protein complexes
seems to occur more rapidly in PK-treated than in PK-
untreated samples. These results suggest a differential
binding response of plasminogen to PK treated and
untreated PrP aggregates. Variations in velocity parame-
ters observed could be explained by the formation of two
different types of aggregates possibly very similar in size
but different in the structure and the amount of accessible
groups at the surface of the aggregates. Plasminogen is a
blood serum protein, which has been shown to bind to
different molecular surfacesthat contain exposed carboxy-
terminal lysines [11,27]. This interaction is kringle medi-
ated. The mechanisms of binding of PrPSc to plasminogen
are unclear and investigations in this process have been
curtailed by the lack of structural information on the PrPSc
prion protein. However, it has been demonstrated that the
interaction of plasminogen to PrPSc aggregates is lysine
mediated [10]. Sheep prion protein contains several clus-
ters of lysine residues in the core (104, 107, 109, 113, 188,
197, and 207) and also in the flexible tail (25, 26, and
29). The N-terminal core of the protein is a flexible
extended tail, thus it is very sensitive and susceptible to
the degradation by PK regardless the source of PrPSc [28].
It is possible that the treatment of PrPSc aggregates with
proteinase K not only may remove important lysine bind-
ing sites but induce a conformational change leading to
molecular structural rearrangement that might masks
binding sites and other parts of the PrP molecule. New
structural rearrangement of aggregates could induce a
decrease in the ligand-binding efficiency of plasminogen
kringles. Proteins with carboxy-terminal lysyl residues
appear to function as plasminogen binding sites [27].
However, it is known that other structural characteristics
of peptides and proteins, such the presence of additional
lysyl residues proximal to the aminus terminus, can
increase their affinity for plasminogen [27]. Several stud-
ies performed with recombinant prion protein have dem-
onstrated the importance of n-terminal sequences in
enhancing plasminogen binding activity [22,29].
If two different structural types of aggregates exist, with
the PK-untreated type having a higher affinity for plas-
minogen than the PK-treated type, then, differences in
velocity changes between PK-treated and untreated sam-
ples may be expected. Contributions to velocity changes
depend on the elastic properties of the newly protein-pro-
tein network and therefore on the number of involved
interactions between aggregate particles. In the case of PK-
untreated samples the protein network is rapidly formed
and stabilized by lysine interacting plasminogen kringles.
In contrast, PK-treated aggregates which are not able to
form additional bonds interact slowly with plasminogen
forming protein-protein complex of reduced stability. The
faster rate of binding on PK-untreated samples compared
to PK-treated could be explained in terms of binding
cooperativity. Ryou et al. [22], showed a positive coopera-
tive binding process between kringle domains and recom-
binant PrP.
Changes in ultrasonic velocity and attenuation observed
during the course of the experiments suggest that consid-
erable physicochemical alterations were occurring in the
solution. Ultrasonic velocity is determined by the density
and elastic response of the medium to the oscillating pres-
sure and this parameter can be expressed in terms of com-
pressibility [30]. An increase on ultrasonic velocity at
initial stages of the reaction suggests that both conforma-
tional changes and protein-protein complex formation
processes took place during the binding event. Both,BMC Biotechnology 2007, 7:43 http://www.biomedcentral.com/1472-6750/7/43
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chemical interactions, involved in the binding process of
plasminogen to PrPSc, along with structural characteristics
of the newly formed protein network, could have contrib-
uted to the positive velocity changes observed. Conforma-
tional changes in the plasminogen protein molecule upon
binding possibly contributed to the increment observed
in the velocity values by decreasing the compressibility of
the system. Significant conformational changes involving
changes from a compact structure to a less compact in
binding to small molecules such as aminocarboxylic acids
or proteins such as fibrin have been frequently reported
[31-33]. A change from a closed to an open conformation
has been reported to occur, upon binding of plasminogen
to a ligand. It has been suggested that this conformational
change is able to produce a decrease in the system volume
possibly due to the increase in exposure of surface area to
the solvent, disruption of electrostatic interactions and
decrease of size voids [34]. The increase in exposure of the
protein to water molecules (i.e. hydration) has a signifi-
cant effect on the ultrasonic velocity. An increase of water
in the hydration shell of the solute molecules results in a
rise in ultrasonic velocity in solutions due to lowering in
the compressibility of the overall system. In the present
study, similar factors contributing to a decrease in the
compressibility of the system were expected to occur upon
this type of conformational change. The increase in veloc-
ity is consistent with the protein changing from a compact
to a more loosening structure. It was interesting that the
most consistent profiles were detected at the most dilute
concentration of homogenate (2%). As proteins change in
conformation, cavities in the interior of the molecule are
created and a rearrangement of atomic groups take place.
Groups that were initially buried within the molecule may
become exposed during the conformational transforma-
tion inducing variations in the hydrogen bonding and
hydrophobic interactions of the protein. Positive velocity
changes could also be related to the changes on elasticity
in the solution due to the formation of the protein-pro-
tein network. Elasticity can been used to characterize pro-
tein network formation. Formation of a protein network
introduces resistance to deformation and elasticity. As the
protein-protein network is formed, the medium become
more rigid and compact, so the velocity of the sound will
be expected to increase in this new less elastic medium.
Eventually, this protein interacting network precipitates
restoring the initial medium properties. Precipitation was
indicated by a decrease in velocity values. It is probable
that the reaction conditions in the 2% homogenate was
most favourable to detecting these molecular interactions.
Conclusion
this study highlights the potential of the HR-US system to
detect plasminogen-PrPsc aggregates and to discriminate
between PrP isoforms. The specificity of the interaction of
plasminogen to PrPSc was demonstrated on scrapie PK-
untreated and PK-treated samples and confirmed on
healthy brain samples. This test is significant as it does not
require a proteinase-K pretreatment step, which consider-
ably improves the specificity of the assay.
Methods
Principles of plasminogen capture ultrasonic assay
In this study, the ultrasonic system was used to continu-
ously monitor the binding reaction of plasminogen to
sheep PrPSc with the aim of differentiating scrapie affected
from non-affected brain tissues. Various preparations
from normal or scrapie-affected brains were prepared,
each at three different homogenate concentrations (2, 5,
and 10%) and incubated with plasminogen coated beads
in an HR-US cell. Incubation conditions were optimised
to promote preferential binding of PrPSc to plasminogen
(J. Grassi, personal communication). Both PK digested
and undigested homogenates were tested in order firstly
to investigate the specificity of PrPSc binding in the pres-
ence of PrPc and secondly, to investigate the possibility
that a digestion step might be capable of being omitted –
a great advantage should a TSE diagnostic assay be devel-
oped.
Experimental procedures
Covalent coupling of plasminogen to magnetic beads
Coupling of plasminogen to magnetic beads was per-
formed following manufacturer's instructions. Briefly,
100 μg of human plasminogen (Sigma) was covalently
bound to paramagnetic Tosyl-activated beads (M-280
Dynabeads, 2 ml) purchased from Dynal (Oslo) in 1 ml
of coupling buffer (0.1 M borate pH 9.5). After incubation
for 48 hours at 4°C, the beads were washed twice with
phosphate buffered saline (PBS), containing 0.1% (w/v)
BSA, for 5 min. Blocking of free tosyl-groups was accom-
plished by incubating the beads with 0.2 M Tris pH 8.5
containing 0.1% (w/v) BSA for 24 h at 20°C. Finally,
beads were washed once in PBS pH 7.4 containing 0.1%
(w/v) BSA for 5 min at 4°C and made up to a final con-
centration 2 × 109/ml in PBS/BSA buffer containing
0.02% sodium azide. The coated bead suspension was
stored at 4°C in.
Brain tissues and homogenate sample preparation
Brain tissues (cerebellum) were kindly supplied by the
CVRL (Abbotstown). Scrapie affected tissues were from
naturally infected sheep. Animals (two male and 3
female) were aged between 2–4 years of age Samples were
collected at post-mortem and scrapie diagnosed by his-
topathology and confirmed by immunohistochemistry.
Homogenates (20% w/v in 5% sucrose) of brains from
five normal and five scrapie infected sheep were prepared
and aliquots were stored at -20°C. Duplicate aliquots
were brought to 2, 5 or 10% by dilution with ice-cold cap-
ture buffer (0.1 M phosphate buffer pH 7.4, 0.5% M NaCl,BMC Biotechnology 2007, 7:43 http://www.biomedcentral.com/1472-6750/7/43
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0.1% Sarkosyl) with or without PK (Sigma). Samples
digested with PK were incubated with 5 μg/ml at 37°C for
20 min. The digestion was terminated by addition of Pefa-
bloc (protease inhibitor purchased from Sigma) to a final
concentration of 4 mM. Pefabloc at the same final concen-
tration was also added to the undigested brain samples.
High-resolution ultrasonic spectroscopy analyses
Ultrasonic velocity and attenuation were measured using
a HR-US 102 ultrasonic spectrometer from Ultrasonic Sci-
entific Ltd.; cell temperature (25°C) was controlled with a
Haake F8 water circulator bath (Haake C5) (Karlsruhe,
Germany). Measurements were taken at different frequen-
cies, 5000, 8000 and 11400 MHz, the margin of error
being 0.2 mm/s and 0.1% for velocity and attenuation
respectively. All measurements were carried out in a differ-
ential mode with two identical acoustical resonator cells:
a measuring and a reference cell. Solutions were degassed
prior to loading into the resonance cells. A volume of 900
μl of brain homogenate, prepared in capture buffer, was
added to the measuring cell and the reference cell was
filled with the same volume of capture buffer only. Prior
to ultrasonic measurements the samples were allowed to
equilibrate to the desired temperature (25°C) for approx-
imately 20 minutes. Each reaction was initiated by addi-
tion of a solution of plasminogen coated beads in a single
10-μl aliquot (2 × 107 beads) to both measuring and ref-
erence cells, the solution being delivered with a Hamilton
syringe by injection through a small hole in the lid of each
cell. Reaction mixtures were kept constantly stirred at 700
rpm. Changes in velocity and attenuation in both cells
were continuously monitored for 3–4 hours and the dif-
ference between measuring and reference cells was auto-
matically calculated and recorded. Control experiments
without beads were performed under the same conditions
as described above, a 10-μl aliquot of capture buffer rather
than beads being injected into the measuring and refer-
ence cell. All experiments were performed in duplicate or
triplicate. Data were analysed using a general linear model
repeated measures analysis of variance.
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Illustration of ultrasonic velocity (dU) profiles of PK-untreated and PK-treated scrapie infected and healthy brain homogenates  prepared at 2% Figure 2
Illustration of ultrasonic velocity (dU) profiles of PK-untreated and PK-treated scrapie infected and healthy brain homogenates 
prepared at 2%. Binding reaction was performed in the reaction buffer at 25°C. A 10 ul-buffer solution containing plasminogen 
coated beads (2 × 107) was added to each sample (t = 0). Scrapie PK-untreated (black triangle), PK-treated (grey triangle) and 
healthy PK-untreated (black circle) and PK-treated (grey circle) are shown over approximately 3-hour of the reaction.
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